Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Dubovsky

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
The Pediatric Infectious Disease Journal|April 3, 2012
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in childrenStan L Block, Judith Falloon, Jeffrey A Hirschfield, et al.
Influenza and Other Respiratory Viruses|October 16, 2012
Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*Eric A Sheldon, Robert Jeanfreau, Joseph A Sliman, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated InfluenzaS Omar Ali, Therese Takas, Andrew Nyborg, et al.
The Journal of Infectious Diseases|May 13, 2009
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urineDavis C Nwakanma, Natalia Gomez-Escobar, Michael Walther, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy AdultsM Pamela Griffin, Anis A Khan, Mark T Esser, et al.
Plos One|November 10, 2010
Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trialsRaburn M Mallory, Elissa Malkin, Christopher S Ambrose, et al.
The Pediatric Infectious Disease Journal|January 27, 2018
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm InfantsJoseph B Domachowske, Anis A Khan, Mark T Esser, et al.
Plos Medicine|October 1, 2021
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trialNeil Formica, Raburn Mallory, Gary Albert, et al.
The Journal of Infectious Diseases|October 14, 2017
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older AdultsJudith Falloon, Jing Yu, Mark T Esser, et al.
Vaccine|April 23, 2016
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvantJudith Falloon, Fei Ji, Craig Curtis, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
The Pediatric Infectious Disease Journal|April 3, 2012
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in childrenStan L Block, Judith Falloon, Jeffrey A Hirschfield, et al.
Influenza and Other Respiratory Viruses|October 16, 2012
Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*Eric A Sheldon, Robert Jeanfreau, Joseph A Sliman, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated InfluenzaS Omar Ali, Therese Takas, Andrew Nyborg, et al.
The Journal of Infectious Diseases|May 13, 2009
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urineDavis C Nwakanma, Natalia Gomez-Escobar, Michael Walther, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy AdultsM Pamela Griffin, Anis A Khan, Mark T Esser, et al.
Plos One|November 10, 2010
Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trialsRaburn M Mallory, Elissa Malkin, Christopher S Ambrose, et al.
The Pediatric Infectious Disease Journal|January 27, 2018
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm InfantsJoseph B Domachowske, Anis A Khan, Mark T Esser, et al.
Plos Medicine|October 1, 2021
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trialNeil Formica, Raburn Mallory, Gary Albert, et al.
The Journal of Infectious Diseases|October 14, 2017
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older AdultsJudith Falloon, Jing Yu, Mark T Esser, et al.
Vaccine|April 23, 2016
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvantJudith Falloon, Fei Ji, Craig Curtis, et al.
Pageof 6